AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Akeso's Ivonescimab Shows Survival Benefit in Lung Cancer Trial, Challenging Merck's Keytruda Franchise
ByAinvest
Wednesday, Aug 27, 2025 2:47 pm ET1min read
Akeso and Summit Therapeutics reported that ivonescimab, a PD-1xVEGF bispecific antibody, extended patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The final overall survival analysis of the phase 3 HARMONi-A study showed that ivonescimab met the OS clinical endpoint. Detailed results will be presented at an upcoming medical conference. HC Wainwright raised Summit's price forecast from $44 to $50, citing a higher probability of approval in NSCLC to 85%.
Akeso and Summit Therapeutics have reported encouraging results for their drug, ivonescimab, in the treatment of non-small cell lung cancer (NSCLC). The phase 3 HARMONi-A study showed that ivonescimab, a PD-1xVEGF bispecific antibody, extended patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. The final overall survival (OS) analysis demonstrated that ivonescimab met the OS clinical endpoint [1].The study compared ivonescimab plus platinum-doublet chemotherapy to a placebo plus platinum-doublet chemotherapy. The results indicated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a hazard ratio of 0.52 [2]. This data suggests that ivonescimab could challenge Merck's Keytruda, which previously failed to show an OS benefit in this setting.
The companies plan to present detailed results at an upcoming medical conference. Analysts have reacted positively to the news, with HC Wainwright raising Summit's price forecast from $44 to $50, citing a higher probability of approval in NSCLC to 85% [2].
References:
[1] https://www.statnews.com/2025/08/26/akeso-says-its-closely-watched-drug-improved-patient-survival-in-a-lung-cancer-trial/
[2] https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47367794/summit-akeso-report-lung-cancer-survival-boost-with-ivonescimab-a-rival-to-mercks-keytruda-multi-billion-dollar-franchise-says-analyst
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet